Notice of Application - 2012
[Federal Register Volume 77, Number 54 (Tuesday, March 20, 2012)]
[Notices]
[Page 16261]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-6701]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances, Notice of Application,
Cerilliant Corporation
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on July 21, 2011, Cerilliant Corporation, 811 Paloma Drive, Suite
A, Round Rock, Texas 78665-2402, made application by letter to the Drug
Enforcement Administration (DEA) to be registered as an importer of the
following basic classes of controlled substances:
| Drug |
Schedule |
| 4-methyl-N-methylcathinone (1248) |
I |
| 1–Pentyl-3-(1-naphthoyl)indole (7118) |
I |
| 1–Butyl-3-(1-naphthoyl)indole (7173) |
I |
| 1-[2-(4–Morpholinyl)-ethyl]-3-(1-naphthoyl)indole (7200) |
I |
| 5-(1,1–Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7297) |
I |
| 5-(1,1–Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]phenol (7298) |
I |
| 3,4-methylenedioxypyrovalerone (7535) |
I |
| 3,4-methylenedioxy-N-methylcathinone (7540) |
I |
| Desomorphine (9055) |
I |
The company plans to import small quantities of the listed
controlled substances for the manufacture of analytical reference
standards.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 19, 2012.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: March 8, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-6701 Filed 3-19-12; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
